Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROCAINAMIDE HCL vs DISOPYRAMIDE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Class Ia antiarrhythmic agent; blocks sodium channels, decreases phase 0 slope of action potential, prolongs refractory period, and increases action potential duration.
Class Ia antiarrhythmic agent; inhibits cardiac sodium channels, prolongs action potential duration, increases effective refractory period, and reduces myocardial excitability and conduction velocity.
Treatment of documented ventricular arrhythmias (e.g., sustained ventricular tachycardia) that are life-threatening,Off-label: Atrial fibrillation, atrial flutter, supraventricular tachycardia, Wolff-Parkinson-White syndrome
Treatment of life-threatening ventricular arrhythmias (e.g., sustained ventricular tachycardia),Suppression of symptomatic atrial fibrillation/flutter
For life-threatening ventricular arrhythmias, IV: Loading dose: 100 mg administered at a rate of 25-50 mg/min, may repeat every 5 minutes until arrhythmia suppressed or up to a total of 500-1000 mg. Maintenance: IV infusion 1-4 mg/min. Oral: 250-500 mg every 3-6 hours; maximum 4 g/day.
100-200 mg orally every 6 hours; immediate-release: 100-200 mg every 6 hours; extended-release: 200-300 mg every 12 hours.
Terminal elimination half-life: 2.5-4.7 hours (3 hours typical) in normal renal function; prolonged to 11-20 hours in renal impairment; NAPA half-life 6-8 hours (prolonged in renal failure).
Terminal elimination half-life: 6-8 hours (normal renal function); prolonged to 15-25 hours in renal impairment (creatinine clearance <40 m L/min), requiring dose adjustment.
Hepatic via N-acetyltransferase (NAT2) to N-acetylprocainamide (NAPA); also undergoes hydrolysis to p-aminobenzoic acid.
Primarily hepatic metabolism via CYP3A4; approximately 40-60% excreted unchanged in urine.
Primarily renal (50-60% unchanged via glomerular filtration and tubular secretion) with 10-30% as N-acetylprocainamide (NAPA) metabolite; minor biliary/fecal (<5%).
Renal excretion of unchanged drug accounts for 40-60% of elimination; hepatic metabolism (N-dealkylation) accounts for 20-30%; approximately 10-15% excreted in feces via biliary elimination.
15-25% bound primarily to alpha-1-acid glycoprotein and albumin.
50-65% bound to plasma proteins (primarily to alpha-1-acid glycoprotein, with lower affinity to albumin).
1.5-2.5 L/kg (approximates total body water; indicates extensive tissue distribution).
0.8-1.4 L/kg (extensive tissue distribution; higher in myocardial tissue than plasma).
Oral: 75-95% (immediate-release); IM: 100%; IV: 100%.
Oral: 80-90% (immediate-release); 60-80% (sustained-release due to incomplete absorption).
Cr Cl >50 m L/min: No adjustment. Cr Cl 10-50 m L/min: Administer every 6-12 hours. Cr Cl <10 m L/min: Administer every 12-24 hours.
GFR 30-50 m L/min: 100 mg every 8-12 hours; GFR 15-29 m L/min: 100 mg every 12-24 hours; GFR <15 m L/min or dialysis: 100 mg every 24 hours or 50 mg every 12 hours.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 25-50%. Child-Pugh Class C: Reduce dose by 50-75% or avoid use.
Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: avoid use or reduce by 75%.
IV: Loading dose: 15 mg/kg over 30-60 minutes, followed by maintenance infusion of 20-80 mcg/kg/min; maximum 2 g/day. Oral: 15-50 mg/kg/day in divided doses every 3-6 hours; maximum 4 g/day.
Children <1 year: 10-30 mg/kg/day divided every 6 hours; 1-4 years: 10-30 mg/kg/day divided every 6 hours; 4-12 years: 10-30 mg/kg/day divided every 6 hours; adolescents: same as adult dosing up to 400 mg/day.
Start at lower end of dosing range due to age-related decreased renal function and increased risk of hypotension and arrhythmias. Monitor renal function and adjust accordingly.
Start at low end of dosing range (100 mg every 6 hours) due to decreased renal function and increased sensitivity; monitor QTc interval and anticholinergic effects.
Procanamide can cause agranulocytosis, leukopenia, and thrombocytopenia; fatal blood dyscrasias have occurred. Frequent blood counts are recommended.
Disopyramide has negative inotropic effects and may precipitate or exacerbate heart failure. Use with caution in patients with pre-existing heart failure or significant left ventricular dysfunction.
May cause lupus erythematosus-like syndrome (especially with slow acetylator phenotype); proarrhythmic effects (torsades de pointes); hypotension; bone marrow suppression; hepatotoxicity; potentiation of neuromuscular blocking agents.
May worsen or precipitate heart failure due to negative inotropy,Risk of proarrhythmia (e.g., torsades de pointes) especially with hypokalemia or bradycardia,Anticholinergic effects: urinary retention, dry mouth, blurred vision, constipation,May cause hypoglycemia in rare cases,Dose adjustment required in renal or hepatic impairment
Complete heart block; second- or third-degree AV block without pacemaker; long QT syndrome; torsades de pointes; known hypersensitivity to procainamide or any component.
Cardiogenic shock,Pre-existing second- or third-degree AV block (without pacemaker),Known hypersensitivity to disopyramide,Severe heart failure or left ventricular dysfunction
No significant food interactions reported. However, changes in dietary salt intake may affect blood pressure control; avoid excessive caffeine or alcohol as they may trigger arrhythmias. Maintain consistent potassium and magnesium intake; severe electrolyte disbalances can alter drug effect.
Avoid grapefruit juice as it may increase disopyramide concentrations. Limit caffeine intake as it may worsen arrhythmias. Avoid high-fat meals as they may reduce absorption.
FDA pregnancy category C. Procainamide crosses the placenta. In first trimester, risk of congenital anomalies is not well-studied; animal studies show no teratogenicity but use only if clearly needed. In second and third trimesters, chronic use may be associated with fetal bradycardia, QT prolongation, and neonatal lupus syndrome (transient). Avoid in pregnancy if possible.
Disopyramide crosses the placenta. First trimester: No well-controlled studies; potential for adverse effects based on animal data. Second and third trimesters: May stimulate uterine contractions, potentially causing preterm labor; reports of neonatal hypoglycemia and respiratory depression. Not recommended during pregnancy unless benefit outweighs risk.
Procainamide and its active metabolite NAPA are excreted into breast milk. Milk-to-plasma ratio is approximately 0.8-1.3. Concentrations in milk can reach therapeutic levels. Potential for adverse effects in nursing infant, including bradycardia and hypotension. Use with caution, monitor infant. AAP recommends avoiding use if possible.
Disopyramide is excreted into breast milk with milk-to-plasma ratio of approximately 0.9. Infant exposure estimated at 2–6% of maternal weight-adjusted dose. Monitor infant for bradycardia, hypoglycemia, and apnea. Weigh benefits against potential risks.
Pregnancy alters pharmacokinetics: increased volume of distribution may require higher loading doses (25-30% increase). Decreased plasma albumin reduces protein binding, increasing free fraction. Enhanced renal clearance (due to increased GFR) may necessitate more frequent dosing or dose adjustments. Monitor serum concentrations closely. Start with oral doses of 50 mg/kg/day in divided doses, titrate to effect. Intravenous: initial 100 mg every 5 minutes until arrhythmia controlled, then maintenance 2-6 mg/min with adjustments.
Dose may require adjustment due to pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced renal clearance, altered protein binding). Monitor serum disopyramide levels and therapeutic response; consider lower starting doses and titrate to effect.
Procainamide HCL is a Class IA antiarrhythmic used for atrial and ventricular arrhythmias. It can cause lupus-like syndrome, especially in slow acetylators; monitor ANA titers. Renal dose adjustment is critical due to active metabolite N-acetylprocainamide (NAPA) accumulation. Watch for QT prolongation and torsades de pointes; avoid with other QT-prolonging drugs. Administer IV slowly to avoid hypotension; oral loading requires hepatic first-pass consideration.
Disopyramide is a class IA antiarrhythmic with significant negative inotropic and anticholinergic effects. Avoid in patients with heart failure, cardiogenic shock, or glaucoma. Dose adjustment required in renal impairment. Monitor QRS and QT intervals; proarrhythmia risk. May cause hypoglycemia in elderly or diabetic patients. Therapeutic drug monitoring recommended (target 2-5 mcg/m L).
Take this medication exactly as prescribed; do not double doses if missed.,Report any symptoms of lupus (joint pain, rash, fever, chest pain) immediately.,Avoid sudden position changes to prevent dizziness from low blood pressure.,Tell your doctor all other medications, especially other heart rhythm drugs.,You may need regular blood tests to monitor drug levels and organ function.,Do not stop taking this medicine abruptly; sudden stop may worsen arrhythmia.,If using extended-release tablets, do not crush or chew them.
Take exactly as prescribed; do not skip doses or double up.,Do not take with grapefruit juice.,Avoid alcohol and other CNS depressants.,Report symptoms of heart failure (shortness of breath, swelling) or arrhythmia (palpitations, syncope).,May cause dry mouth, blurred vision, urinary retention; use caution driving.,Monitor blood sugar if diabetic.,Do not stop abruptly without consulting your doctor.
"Procainamide is a class IA antiarrhythmic that is primarily metabolized by N-acetyltransferase (NAT) and also undergoes CYP2D6-mediated metabolism. Midostaurin, a multikinase inhibitor used for FLT3-mutated AML, is metabolized mainly by CYP3A4. Procainamide can inhibit CYP3A4, reducing the clearance and increasing plasma concentrations of midostaurin, potentially leading to enhanced toxicity including QT prolongation, hepatotoxicity, and myelosuppression."
"Procainamide, a Class Ia antiarrhythmic, prolongs the QT interval by blocking cardiac sodium channels and delaying repolarization. Paroxetine, a selective serotonin reuptake inhibitor (SSRI), has been associated with QT prolongation, possibly via inhibition of cardiac hERG potassium channels. Concomitant use increases the risk of excessive QT prolongation, potentially leading to torsade de pointes and other ventricular arrhythmias."
"Procainamide, a class Ia antiarrhythmic agent, prolongs the QT interval by blocking cardiac sodium and potassium channels. Pentamidine, used for Pneumocystis pneumonia, also prolongs the QT interval through inhibition of the rapid delayed rectifier potassium current (IKr). Concomitant use can cause additive QT prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias, especially in patients with electrolyte disturbances or renal impairment."
"Disopyramide, a class Ia antiarrhythmic agent, prolongs the QT interval by inhibiting cardiac potassium channels, thereby increasing the risk of torsades de pointes. Paroxetine, a selective serotonin reuptake inhibitor (SSRI), also has dose-dependent QT-prolonging effects, primarily through hERG channel blockade. Concomitant use synergistically lengthens the QT interval, predisposing patients to potentially fatal ventricular arrhythmias, especially in those with pre-existing risk factors such as hypokalemia, bradycardia, or genetic long QT syndrome."
"Disopyramide, a class Ia antiarrhythmic agent, prolongs ventricular repolarization by blocking cardiac sodium and potassium channels. Ezogabine, a potassium channel opener, also has dose-dependent effects on cardiac repolarization. Coadministration may result in additive QT interval prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias."
"Disopyramide, a class Ia antiarrhythmic agent, may potentiate the hypoglycemic effects of cinoxacin, a quinolone antibiotic, by enhancing insulin secretion and increasing peripheral glucose uptake. This interaction can lead to clinically significant hypoglycemia, particularly in patients with diabetes mellitus or those concurrently using other hypoglycemic agents. Patients may experience symptoms such as diaphoresis, palpitations, confusion, or loss of consciousness if blood glucose levels drop precipitously."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROCAINAMIDE HCL vs DISOPYRAMIDE PHOSPHATE, answered by our medical review team.
PROCAINAMIDE HCL is a Antiarrhythmic (Class Ia) that works by Class Ia antiarrhythmic agent; blocks sodium channels, decreases phase 0 slope of action potential, prolongs refractory period, and increases action potential duration.. DISOPYRAMIDE PHOSPHATE is a Antiarrhythmic (Class Ia) that works by Class Ia antiarrhythmic agent; inhibits cardiac sodium channels, prolongs action potential duration, increases effective refractory period, and reduces myocardial excitability and conduction velocity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROCAINAMIDE HCL and DISOPYRAMIDE PHOSPHATE depend on the specific clinical indication. These are both Antiarrhythmic (Class Ia) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROCAINAMIDE HCL is: For life-threatening ventricular arrhythmias, IV: Loading dose: 100 mg administered at a rate of 25-50 mg/min, may repeat every 5 minutes until arrhythmia suppressed or up to a total of 500-1000 mg. Maintenance: IV infusion 1-4 mg/min. Oral: 250-500 mg every 3-6 hours; maximum 4 g/day.. The standard adult dose of DISOPYRAMIDE PHOSPHATE is: 100-200 mg orally every 6 hours; immediate-release: 100-200 mg every 6 hours; extended-release: 200-300 mg every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining PROCAINAMIDE HCL and DISOPYRAMIDE PHOSPHATE. The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Procainamide. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. PROCAINAMIDE HCL is classified as Category A/B. FDA pregnancy category C. Procainamide crosses the placenta. In first trimester, risk of congenital anomalies is not well-studied; animal studies show no teratogenicity but use onl. DISOPYRAMIDE PHOSPHATE is classified as Category D/X. Disopyramide crosses the placenta. First trimester: No well-controlled studies; potential for adverse effects based on animal data. Second and third trimesters: May stimulate uteri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.